Suggested remit: To appraise the clinical and cost effectiveness of olaparib in combination with bevacizumab within its marketing authorisation as maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy.
Status In progress
Process STA 2018
ID number 1652

Provisional Schedule

Committee meeting: 1 08 September 2020
Expected publication 18 November 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors AstraZeneca
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Ovacome
  Ovarian Cancer Action
  Target Ovarian Cancer
Professional groups British Gynaecological Cancer Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Obstetricians & Gynaecologists


Comparator companies Roche
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Medicines and Healthcare products
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
08 January 2020 Invitation to participate
11 November 2019 - 09 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 April 2019 In progress. DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance